Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Allist Pharmaceuticals, Inc.
Eli Lilly and Company
Pfizer
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Quanta Therapeutics
R-Pharm
Incyte Corporation
M.D. Anderson Cancer Center
Novartis
Genentech, Inc.
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
FBD Biologics Limited
Alliance for Clinical Trials in Oncology
Boehringer Ingelheim
Memorial Sloan Kettering Cancer Center
Gruppo Oncologico del Nord-Ovest
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Mirati Therapeutics Inc.
M.D. Anderson Cancer Center
University of Wisconsin, Madison
Pfizer
Sun Yat-sen University
Quanta Therapeutics
Groupe Oncologie Radiotherapie Tete et Cou
Washington University School of Medicine
University of California, San Diego
University of California, San Diego
InventisBio Co., Ltd
Mirati Therapeutics Inc.
Erasca, Inc.
US Oncology Research
University of Colorado, Denver
Academic and Community Cancer Research United
Ono Pharmaceutical Co. Ltd
University College, London
RenJi Hospital